EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6–35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial

Yoonsun Yoon iD, Hye-Kyung Cho iD, Ki Hwan Kim iD, Su Eun Park iD, Yae-Jean Kim iD, Jina Lee iD, Hwang Min Kim iD, Nam Hee Kim iD, Dae Sun Jo iD, Eun Young Cho iD, Seon Hee Shin iD, Jong-Hyun Kim iD und 4 weitere

Vaccines · 13.04.2026 · 14 (4) · 341

DOI: 10.3390/vaccines14040341 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Vaccines, online erschienen am 13.04.2026. Verfasst von Yoonsun Yoon und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Korea University College of Medicine, Seoul 02841, Republic of Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SK bioscience (Seongnam, Republic of Korea).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Influenza causes substantial morbidity in young children, particularly those aged 6–35 months. In this age group, optimisation of vaccine dose regimens remains important to ensure adequate immunogenicity while maintaining acceptable safety. This study evaluated the immunogenicity and safety of a full 0.5 mL dose of quadrivalent inactivated influenza vaccine (NBP607-QIV) in young children.

Methods

This Phase 3, randomised, double-blind, active-controlled, multicentre study was conducted in Korea, Thailand, and Malaysia. Healthy children aged 6–35 months were randomised 2:1 to receive NBP607-QIV (0.5 mL) or control vaccine (0.25 mL). Immunogenicity was assessed using the haemagglutination inhibition assay. Primary endpoints were non-inferiority of NBP607-QIV versus Agrippal for seroconversion rate (SCR) and adjusted post-vaccination geometric mean titre (GMT) ratio against three shared strains. Immunogenicity against the additional B/Yamagata strain was evaluated according to Committee for Medicinal Products for Human Use (CHMP) criteria. Safety was assessed based on adverse events.

Results

A total of 676 participants were randomised, and 675 were included in the safety set. Non-inferiority of NBP607-QIV versus control vaccine was demonstrated for SCR for all shared strains and for the adjusted GMT ratio for A/H1N1 and B/Victoria, but not for A/H3N2. Immunogenicity against the B/Yamagata strain met CHMP criteria for SCR and geometric mean ratio (GMR). Immunogenicity was consistent across prespecified subgroups, and the incidence of adverse events was comparable between groups, with no clinically meaningful safety concerns.

Conclusions

NBP607-QIV administered at a 0.5 mL dose demonstrated acceptable immunogenicity and a safety profile comparable to that of a licensed trivalent influenza vaccine in children aged 6–35 months, supporting its use in this paediatric population.

Schlagwörter

Stichwörter der Autor:innen

cell culture techniqueschildrenclinical trialimmunogenicityinactivated vaccinequadrivalent influenza vaccinessafetyseasonal influenza

Autor:innen und Institutionen

  • Department of Pediatrics, Korea University College of Medicine, Seoul 02841, Republic of Korea.
  • Department of Pediatrics, Gachon University College of Medicine, Incheon 21565, Republic of Korea.
  • Department of Pediatrics, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 21431, Republic of Korea.
  • Department of Pediatrics, Pusan National University College of Medicine, Yangsan 50612, Republic of Korea.
  • Department of Pediatrics, School of Medicine, Sungkyunkwan University, Seoul 06351, Republic of Korea.
  • Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.

ORCID-Profile: Yoonsun Yoon, Hye-Kyung Cho, Ki Hwan Kim, Su Eun Park, Yae-Jean Kim, Jina Lee, Hwang Min Kim, Nam Hee Kim, Dae Sun Jo, Eun Young Cho, Seon Hee Shin, Jong-Hyun Kim, Ji Hwa Ryu, Ho Keun Park, Yoonyeong Lee, Yun-Kyung Kim

Förderung

  • SK bioscience (Seongnam, Republic of Korea)

Zitieren

APA

Yoon, Y., Cho, H. K., Kim, K. H., Park, S. E., Kim, Y. J., Lee, J., Kim, H. M., Kim, N. H., Jo, D. S., Cho, E. Y., Shin, S. H., Kim, J. H., Ryu, J. H., Park, H. K., Lee, Y., & Kim, Y. K. (2026). Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6–35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial. Vaccines, 14(4), 341. https://doi.org/10.3390/vaccines14040341

Vancouver

Yoon Y, Cho HK, Kim KH, Park SE, Kim YJ, Lee J, et al. Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6–35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial. Vaccines. 2026;14(4):341. doi:10.3390/vaccines14040341

BibTeX
@article{Yoon2026,
  author = {Yoon, Yoonsun and Cho, Hye-Kyung and Kim, Ki Hwan and Park, Su Eun and Kim, Yae-Jean and Lee, Jina and Kim, Hwang Min and Kim, Nam Hee and Jo, Dae Sun and Cho, Eun Young and Shin, Seon Hee and Kim, Jong-Hyun and Ryu, Ji Hwa and Park, Ho Keun and Lee, Yoonyeong and Kim, Yun-Kyung},
  title = {Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6–35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {4},
  pages = {341},
  doi = {10.3390/vaccines14040341}
}
Kostenlos starten →